Mutations in TGFBR2, a component of the transforming growth factor (TGF)-β signaling pathway, occur in high-frequency microsatellite instability (MSI-H) colorectal cancer (CRC). In mouse models, Tgfbr2 inactivation in the intestinal epithelium accelerates the development of malignant intestinal tumors in combination with disruption of the Wnt-β-catenin pathway. However, no studies have further identified the genes influenced by TGFBR2 inactivation following disruption of the Wnt-β-catenin pathway. We previously described CDX2P-G19Cre;Apc flox/flox mice, which is stochastically null for Apc in the colon epithelium.
;Tgfbr2
flox/flox mice, with simultaneous loss of Apc and Tgfbr2. These mice developed tumors, including adenocarcinoma in the proximal colon. We compared gene expression profiles between tumors of the two types of mice using microarray analysis. Our results showed that the expression of the murine homolog of GSDMC was significantly upregulated by 9. mice. We then investigated the role of GSDMC in regulating CRC tumorigenesis. The silencing of GSDMC led to a significant reduction in the proliferation and tumorigenesis of CRC cell lines, whereas the overexpression of GSDMC enhanced cell proliferation. These results suggested that GSDMC functioned as an oncogene, promoting cell proliferation in colorectal carcinogenesis. In conclusion, combined inactivation of both Apc and Tgfbr2 in the colon epithelium of a CRC mouse model promoted development of adenocarcinoma in the
Introduction
The classic paradigm of colorectal cancer (CRC) formation follows the adenoma-carcinoma sequence, in which CRC begins as an adenoma [1] . Additionally, CRC can be classified into two predominant forms of genomic instability: chromosome instability (CIN) and microsatellite instability (MSI). The subclass of MSI accounts for about 15% of CRCs and results from dysfunction of the DNA mismatch repair system [2] [3] [4] [5] .
Transforming growth factor (TGF)-β signaling has the potential to function as a tumor suppressor and regulates various biological processes, including cell growth, differentiation, apoptosis, extracellular matrix modeling, and immune response [6] . TGF-β signal inactivation occurs in many cancers, including pancreatic, breast, and colorectal cancer. In CRC, the components of the TGF-β signaling pathway, specifically TGFBR2 and Smad4, are frequently mutated [7, 8] . TGFBR2 mutations occur in the latter phase of CRC carcinogenesis when adenoma transitions to carcinoma in approximately 60-90% of high-frequency microsatellite instability (MSI-H) CRCs [9] [10] [11] [12] [13] . In clinical studies examining how mutations in the TGFBR2 gene affect the development of MSI-H CRCs, tumors with TGFBR2 mutations were shown to be more frequently located in the right-sided colon, usually had a poor degree of differentiation, tended to appear more frequently as Dukes B stage, and had worse prognoses than those without mutations, indicating that TGFBR2 mutations contributed to tumor progression through the MSI pathway [14] . However, MSI-H tumors with TGFBR2 mutations have been shown to be associated with better prognoses in resected stage III CRCs [9] but similar prognoses to those without TGFBR2 mutations in a population-based study [15] . Thus, the association between prognosis and TGFBR2 mutations in MSI-H CRCs is unclear.
The effects of TGFBR2 mutations in the intestinal epithelium in cancer formation have also been studied in several genetically engineered mouse models [16] . Although Tgfbr2 inactivation alone does not cause tumor-related changes, Tgfbr2 conditional knockout mouse models have indicated that Tgfbr2 inactivation in the intestinal epithelium accelerates the development of malignant intestinal tumors in combination with mutations in Apc [17] , Kras [18] , or Pten [19] . Therefore, such in vivo studies have demonstrated that TGFBR2 inactivation acts synergistically with other aberrant signaling pathways that are often deregulated in CRC, such as the Wnt-β-catenin, RAS-RAF, and phosphoinositol 3-kinase (PI3K) pathways, to promote tumor development. However, no in vivo studies have identified the genes influenced by TGFBR2 inactivation in the context of Wnt-β-catenin signaling disruption during colon tumor formation. These previously established CRC mouse models exhibited tumors predominantly in the small intestine. However, to mimic CRC, the ideal model would exhibit tumors in the colon because cellular responses to TGF-β signaling depend on the cell type and physiological condition [20, 21] . Our prior studies had revealed that mice carrying transgenes regulated by a 9.5-kb fragment containing 5 0 -flanking sequences from the human CDX2 promoter (CDX2P9.5) showed tightly restricted transgene expression in the colon epithelium [22] . Moreover, CDX2P9.5-G19Cre;Apc flox/flox mice exhibited bi-allelic Apc inactivation in the colon epithelium initiated with stochastic activation of Cre recombinase with 19 guanine nucleotides (G19Cre) introduced downstream of the initiating ATG codon, followed by a frameshift reversion mutation in mononucleotide repeats [23] [24] [25] . This mouse model developed many polypoid tumors, including noninvasive adenocarcinoma, in the proximal colon.
In this study, we generated CDX2P-G19Cre;Apc flox/flox ;Tgfbr2 flox/flox mice lacking Tgfbr2 and Apc protein specifically in the colon epithelium. We then compared the comprehensive gene expression profiles of tumors from Apc mutant mice and Apc/Tgfbr2 mutant mice using microarray analysis. This analysis allowed us to elucidate the mechanisms inducing the characteristics of CRC with TGFBR2 mutation and identify genes that may act as biomarkers or therapeutic targets in CRCs harboring TGFBR2 mutations.
Materials and Methods

Ethics statements
This study was performed in strict accordance with the Guide for the Care and Use of Laboratory Animals and the local committee for animal experiments. All animal protocols were approved by the Institutional Animal Care and Use Committee of Hiroshima University (Permit Number: A15-57). We checked the body weights of the mice every day, and euthanized them immediately after weight loss was detected. Surgery was performed under sodium pentobarbital anesthesia, and all efforts were made to minimize the suffering of the mice. Mice were euthanized by CO2 asphyxiation as per IACUC guidelines. 
Generation of mouse lines
;Tgfbr2
flox/flox mice and CDX2P-G19Cre;Apc flox/flox mice. All mice were housed under specific pathogen-free conditions. Teklad Mouse Breeder Diet 8626 (Harland-Teklad) and automatically supplied water were provided to all mice used in tumorigenesis experiments. The breeding room was maintained at a constant temperature of 23˚C ± 2˚C, relative humidity of 50% ± 5%, 15-20 air changes per hour, and a 12-h light/dark cycle, with lights on at 8:00 am. Four or five mice were housed per cage with chopped wood bedding. Genotyping of Apc and Tgfbr2 alleles was performed with genomic DNA extracted from mouse tails, as described previously [24, 26] .
Tissue harvesting and fixation
After necropsy, the gastrointestinal tracts of mice were removed and analyzed for macroscopically visible lesions. The tissues were washed with PBS containing 0.01% Triton X-100 at 4˚C with agitation. For pathological analyses and tRNA extraction, one part of the tumor tissue was fixed in 4% paraformaldehyde and embedded in paraffin, and the other part was embedded in OCT compound (Sakura Finetek Japan, Tokyo, Japan), rapidly frozen, and stored in liquid nitrogen.
Laser capture microdissection and gene expression profiling
Tissues were fixed in OCT compound, and frozen sections (12 μm) were then cut, dehydrated, and stained with hematoxylin. tRNA was extracted from cancer tissues dissected with a LMD6500 laser capture microdissection device (Leica MICROSYSTEMS, Tokyo, Japan), and samples with an RNA integrity number greater than 6.0 were analyzed further. Gene expression profiling was compared between CDX2P-G19Cre;Apc 
qRT-PCR
cDNA was generated using a QuantiTect Reverse Transcription Kit (Qiagen, Valencia, CA, USA) and was amplified with a Rotor-Gene Q 2PLEX HRM Real-Time PCR system (Qiagen).
The qPCR mixture was prepared in a final volume of 25 μL, including 2× Rotor-Gene SYBR Green PCR Mix (Qiagen), 10 μM forward/reverse primers, and 32 ng cDNA. The amplification protocol consisted of denaturation at 95˚C for 5 min, followed by 40 cycles of 95˚C for 5 s and 60˚C for 10 s. Beta-2-microglobulin (B2M) was used as an internal control. The PCR primers used for gene analysis are shown in S1 Table. Immunohistochemistry
For mouse tissues, we carried out immunohistochemical staining of β-catenin and immunofluorescence staining of Tgfbr2 with a rabbit anti-mouse TGFβRII polyclonal antibody (sc-220; Santa Cruz Biotechnology, Dallas, TX, USA) as previously described [30, 31] . For human tissues, formalin-fixed, paraffin-embedded samples were sectioned to 5-μm-thick sections and stained for GSDMC using a Catalyzed Signal Amplification System (Dako Japan, Tokyo, Japan), which is based on streptavidin-biotin-horseradish peroxidase complex formation. After deparaffinization and rehydration, the sections were treated with target retrieval solution (pH 9.0) at 96˚C for 40 min. A rabbit anti-human GSDMC polyclonal antibody (NBP1-91924; Novus Biologicals, Littleton, CO, USA) were used at a dilution of 1:100, followed by incubation with peroxidase-labeled anti-rabbit IgG for 60 min.
Surgical specimens
We investigated GSDMC mRNA and protein expression in cancer and corresponding adjacent normal colonic tissues for 44 consecutive CRCs resected at the Hiroshima University Hospital (Hiroshima, Japan) from 2013 to 2014. Patient characteristics were collected from a prospective database, and CRC was staged according to the American Joint Commission for Cancer Staging (6th edition). Written informed consent for participation in the study was obtained from all participants. This study was approved by Ethical Committee for Epidemiology of Hiroshima University (Permit Number: Epidemiology-744).
Cell lines and reagents
All cell lines were obtained from the American Type Culture Collection (ATCC) from 1998 to 2000. The amphotropic Phoenix packaging cell line was provided by G. Nolan (Stanford University, Palo Alto, CA, USA). Details of cell culture conditions were previously described [32] .
RNA interference
Two siRNA duplexes targeting GSDMC (GSDMC siRNA1 and siRNA2) and a nonsilencing siRNA duplex (MISSION siRNA Universal Negative Control: SIC-002; Sigma Aldrich, Hokkaido, Japan) were synthesized by Sigma Aldrich. Sequences of GSDMC siRNAs are listed in S2 Table. Cells were cultured in antibiotic-free medium for 24 h and then transfected with siRNAs (80 pmol) using Lipofectamine RNAiMAX Transfection Reagent (Life Technologies, Tokyo, Japan). The silencing effect of the siRNAs was examined by qRT-PCR 48 h after transfection.
Plasmid construction
A 1606-bp fragment of the GSDMC allele containing a Flag tag at the 3 0 end was amplified from cDNA of LoVo cells using the indicated primers (S2 Table) and then was inserted into the retroviral expression vector pDON-5 neo (TaKaRa, Shiga, Japan) by SalI/BglII digestion to form the vector pDON-5/GSDMC. All plasmids derived from PCR products were verified by sequencing.
The hairpin-loop oligonucleotides containing GSDMC siRNA2 and nonsilencing siRNA (S2 Table) were synthesized and inserted into pSUPER.retro.neo+gfp (OligoEngine, Seattle, WA, USA) by BglII/HindIII digestion to generate pSUPER/GSDMC shRNA2 and pSUPER/ nonsilencing shRNA.
Retroviral infections
Phoenix packaging cells were transfected with retroviral constructs; supernatants containing nonreplicating amphotropic virus were harvested. For GSDMC overexpression, SW480 and WiDr cells were infected with virus containing pDON-5/GSDMC and pDON-5 vectors. For GSDMC silencing, LoVo cells were infected with virus containing pSUPER/GSDMC shRNA2 and pSUPER/nonsilencing shRNA. Cells were selected with neomycin (500, 600, and 250 μg/ mL, respectively for SW480, WiDr, and LoVo cells) for 2-3 weeks as previously described [32] .
Western blotting
Western blot analysis was performed essentially as previously described [32] . Anti-GSDMC rabbit polyclonal antibodies (TA315616; ORIGENE, CA, USA) and anti-β actin monoclonal antibodies (clone AC-15; Sigma Aldrich) were used at 1:1000 dilutions.
Cell proliferation assays
Cell proliferation was measured using a CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS) kit (Promega KK, Tokyo, Japan). The target cells (700 cells/well) were seeding and incubated in a 96-well plate. MTS reagent (20 μL) was added to each well, and plates were incubated for 2 h in a humidified incubator at 37˚C with an atmosphere containing 5% CO 2 for 0, 48, 96, or 144 h after transfection. The absorbance (A) of each plate was measured at 490 nm. Assays were performed in triplicate.
Soft agar colony formation assays
Colony formation assays were performed in 35-mm dishes as described previously [33, 34] . Assays were performed in triplicate.
In vivo tumorigenesis assays
Female BALB/cA Jcl-nu mice (CLEA Japan, Tokyo, Japan) were used at 5 weeks of age. A total of 1.0 × 10 7 LoVo cells stably expressing GSDMC shRNA2 or nonsilencing shRNA were subcutaneously injected into the right flanks of nude mice. The tumor size was measured by a Vernier caliper every 3 days from days 5-14 after cell implantation. The volume was calculated using the following formula:
, where a is the long diameter, and b is the short diameter. The tumors were removed and weighed on day 14.
Statistical analysis
All values are expressed as means ± standard deviations (SDs). The statistical significance of differences was determined by Mann-Whitney U tests, χ 2 tests, unpaired t test or Fisher's exact tests. Differences with p value of less than 0.05 were considered statistically significant. All statistical analyses were performed using JMP 10 software (SAS Institute Inc.). (Fig 1C-1F ). Both types of genetically engineered mice had distant metastases. Although the morphological phenotypes of the two mouse models did not differ, immunofluorescence staining revealed that intact Tgfbr2 was not expressed in the tumors of CDX2P-G19Cre; Apc flox/flox ;Tgfbr2 flox/flox mice but was expressed in those of CDX2P-G19Cre;Apc flox/flox mice (Fig 1G) . Immunohistochemical staining for β-catenin in serial sections of the tumor indicated nuclear and cytoplasmic accumulation of β-catenin (Fig 1H-1J) , suggesting that the tumors developed through abnormal activation of the Wnt-β-catenin pathway.
Results
CDX2P-
Identification of candidate genes whose expression was altered in response to Tgfbr2 mutation by microarray analysis
Differentially expressed genes were identified as those having a fold-change of at least 2.0 and a p value of less than 0.05 between two groups. Thirteen genes were significantly upregulated, 
GSDMC expression in human CRC
Immunohistological analysis confirmed that GSDMC was not expressed in normal colonic tissues (Fig 3A and 3B) , whereas GSDMC was expressed in the cancer tissues of almost all CRCs (Fig 3C and 3D) . Consistent with these results, qRT-PCR analysis confirmed that GSDMC was upregulated in CRC tissues compared with that in corresponding adjacent normal colonic tissues (Fig 3E) .
Effects of GSDMC silencing and overexpression on cell growth
Next, we analyzed the effects of GSDMC expression on proliferative ability by silencing or overexpressing GSDMC in CRC cell lines. DLD-1 and LoVo cells, which had relatively high endogenous expression of GSDMC mRNA (S1 Fig), were transfected with two small-interfering RNAs (siRNAs) targeting GSDMC. qRT-PCR confirmed that the siRNAs significantly blocked GSDMC expression compared with that in cells transfected with nonsilencing RNA (Fig 4A and 4B) . MTS assays revealed that the proliferation of cells transfected with GSDMC siRNA1 and siRNA2 was inhibited compared with that in cells transfected with nonsilencing RNA (Fig 4C  and 4D ; p < 0.05). Furthermore, in colony formation assays, GSDMC silencing resulted in a significant decrease in anchorage-independent growth ability in DLD-1 cells (Fig 4E; 
GSDMC promoted xenograft tumor growth
To further investigate the importance of GSDMC in colorectal tumorigenesis in an in vivo model, we generated LoVo cell lines stably expressing GSDMC shRNA2 or nonsilencing shRNA. After confirming the stable silencing of GSDMC by qRT-PCR (Fig 5A) , we implanted GSDMC-knockdown cells or control cells into nude mice (n = 8 each). The tumor growth speed in mice inoculated with GSDMC-knockdown cells was significantly slower than that in the control group (Fig 5B) . The volumes of tumors removed from mice inoculated with GSDMC-knockdown cells were smaller than those removed from mice inoculated with control cells (Fig 5C) . Moreover, tumor weights were significantly reduced in mice inoculated with GSDMC-knockdown cells compared with that in mice inoculated with control cells (Fig  5D; 116.6 ± 114.1 versus 315.8 ± 268.8 mg, respectively; p < 0.05). These results indicated that GSDMC played an important role in promoting proliferation in colorectal tumorigenesis in vivo.
Discussion
In this study, we generated a CRC mouse model in which both Tgfbr2 and Apc were inactivated in the colon epithelium; these mutations induce the formation of adenocarcinomas in the proximal colon. We then identified GSDMC as a novel gene upregulated by TGFBR2 inactivation using microarray analysis. Further experiments confirmed that GSDMC promoted tumor cell proliferation in colorectal carcinogenesis. Therefore, GSDMC may be a promising therapeutic target in patients with CRC harboring TGFBR2 mutations.
A previously established CRC mouse model of Tgfbr2 conditional knockout revealed that Tgfbr2 inactivation promoted the progression of adenomas initiated by Apc inactivation to invasive adenocarcinomas with a mucinous component [17] . In human CRC, TGFBR2 exhibited Tgfbr2 and Apc inactivation in the colon epithelium, using previously generated mouse models [22] [23] [24] [25] . Subsequent microarray analysis revealed that Gsdmc4|Gsdmc2 was the most highly upregulated gene between CDX2P-G19Cre;Apc The Gsdm family genes comprise four human genes (GSDMA, GSDMB, GSDMC, and GSDMD) and eight mouse genes (Gsdma1-3, Gsdmc1-4, and Gsdmd). These genes were originally named based on their expression profile; Gsdm family genes are expressed in a cell and tissue type-specific manner in epithelial tissues throughout the gastrointestinal tract and dermis [35, 36] . Additionally, each Gsdm family may be involved in epithelial cell proliferation, differentiation, and apoptosis and may play a crucial role in tumorigenesis in various organs [37] . GSDMC was originally identified as melanoma-derived leucine zipper extranuclear factor (MLZE), whose cDNA was isolated from a melanoma cell line. The mouse homolog of GSDMC consists of four Gsdmc clusters, which exhibit amino acid sequence similarity with each other and are located on chromosome 15 (15D1) [36] . Because the expression levels of individual Gsdmc cluster genes cannot be distinguished from one another due to crossreactivity of microarray probes, Gsdmc4|Gsdmc2 was identified as a significantly upregulated gene pair. However, because other Gsdmc cluster pairs also tended to be upregulated (as shown in S5 Table) , we assumed that Gsdmc1-4 function as a gene cluster and are upregulated by Tgfbr2 mutation. Upregulation of Gsdmc2 and Gsdmc4 was validated in RNA from mouse tumors using specific primers designed for qRT-PCR analysis.
Expression of GSDMC mRNA, which is observed in the epithelium of the esophagus and stomach, is suppressed in gastric and esophageal cancer cell lines, and proliferation assays with gastric cancer cell lines showed that GSDMC has cell-growth inhibitory activity, suggesting that GSDMC may function as a tumor suppressor [37] . In contrast, GSDMC is not expressed in the normal epidermis, but is expressed in melanoma specimens; this expression is correlated with the invasiveness and metastatic potential of melanoma cells [38] . In a recent study, chromosomal engineering in mice showed that copy number gains in the Myc gene promote tumorigenesis in mammary tumors only if the downstream sequence encompassing Pvt1, Ccdc26, and Gsdmc is also amplified [39] , suggesting that GSDMC may play a role in tumor progression. Therefore, the function of GSDMC in carcinogenesis is unclear, and GSDMC may have organ-specific roles. In this study, we investigated the function of GSDMC in CRC. GSDMC was not expressed in normal colonic tissues, but was highly expressed in CRC tissues at both the mRNA and protein levels (Fig 3) . Furthermore, silencing of GSDMC led to a significant reduction in proliferation and tumorigenesis in CRC cell lines in vitro and in vivo, whereas overexpression of GSDMC enhanced CRC cell proliferation in vitro. These results suggested that GSDMC functioned as an oncogene by promoting cell proliferation in colorectal carcinogenesis.
Our studies with the CDX2P-G19Cre;Apc flox/flox ;Tgfbr2 flox/flox mouse model yielded some observations that warrant more detailed investigations. First, the mechanisms through which TGF-β signaling regulate the expression of GSDMC was not determined despite our challenges with the identification of the promoter region of GSDMC, although previous studies have demonstrated that GSDMA in same family members of GSDMC are regulated by TGF-β signaling [40] . However, the available methods are limited in terms of revealing physiological activity in a complex animal [41] . Additionally, in this study, we showed that conditional inactivation of Tgfbr2 in the context of Apc mutation in the colon epithelium results in noninvasive well-differentiated adenocarcinoma, similar to the morphological phenotype observed with Apc mutation alone. This observation may be explained by the fact that Apc homozygous knockout in CDX2P-G19Cre mice induced rapid growth of polypoid tumors, and the mice did not survive for more than 4 weeks. Because Tgfbr2 inactivation was confirmed by genotyping and immunohistochemical analysis in tumors of CDX2P-G19Cre;Apc flox/flox ;Tgfbr2 flox/flox mice, the expression of genes influenced by Tgfbr2 inactivation was assumed to change, and such genes were identified by microarray analysis. However, the mice exhibiting distinct morphological characteristics induced by Tgfbr2 inactivation, such as deep invasiveness and mucinous carcinoma, was a more convincing tool for identifying changes in gene expression induced by Tgfbr2 inactivation. To achieve this, it may be useful to generate a CRC mouse model having haploinsufficiency of Apc, in which tumors develop more slowly and mice live a longer life [42] .
In vitro, TGF-β signaling has been shown to induce growth arrest by inhibiting the expression of cyclins/cyclin-dependent kinases (CDKs) by inducing the CDK inhibitors p15INK4B, p21Cip1, and p27KIP1 and blocking c-myc induction [43, 44, 45, 46, 47] . However, the expression levels of these TGF-β signaling targets were not significantly altered in our microarray analysis. Notably, these genes were identified as targets of TGF-β signaling by in vitro assays, demonstrating the simple additive effects of treatment with TGF-β family ligands. Furthermore, GSDMC was identified in a CRC mouse model involving the microcirculation/stromal microenvironment, which an in vitro system cannot mimic.
In conclusion, we generated a CRC mouse model in which inactivation of Tgfbr2 and Apc in the colon epithelium induced the formation of adenocarcinomas. This unique model has the potential to improve our understanding of CRC with TGFBR2 mutations. Subsequent gene profiling analysis revealed that GSDMC was upregulated by TGFBR2 mutation in CRC. Furthermore, GSDMC promoted tumor cell proliferation in colorectal carcinogenesis and may be a promising therapeutic target for patients with CRC having TGFBR2 mutations. 
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